A randomized, double‐blind, crossover study of the effect of the fluoroquinolone moxifloxacin on glucose levels and insulin sensitivity in young men and women
Authors' conclusion
In young men and women, moxifloxacin, a drug known to block the Kv 11.1 channel, increased QT interval, decreased glucose levels and was associated with increased muscle insulin sensitivity and more frequent episodes of hypoglycaemia.
Study context
- Population
- Young men and women aged 20–40 years, BMI 18.5–27.5 kg/m², without chronic disease38 completed
- Comparison
- Moxifloxacin vs placebo
Methodological detailsdouble-blind, crossover
- Double-blind
- Crossover
Primary result
As reported in the abstract
Glucose regulation (6-h OGTT and CGM)
Moxifloxacin vs PlaceboChange in plasma glucagon (95% CI)P value
Glucose regulation (6-h OGTT and CGM)
17%(4%–33%)
P = 0.03- Reduced with moxifloxacin
- change in early plasma-glucose response (AUC0-30 min) −7% (95% CI −9% to −4%); P < 0.01
- Decreased with moxifloxacin
- change in overall insulin response (AUC0-360 min) −18% (95% CI −24% to −11%); P < 0.01
- Matsuda index insulin sensitivity increased with moxifloxacin
- 11%
- MISI (muscle insulin sensitivity) increased with moxifloxacin
- 34%
Safety
Hypoglycaemia
- Hypoglycaemia more frequent with moxifloxacin, during 8 days of CGM and during OGTTs
- Hypoglycaemia questionnaire scores higher after moxifloxacin
Cardiac effects
- Moxifloxacin prolonged the QTcF interval and increased heart rate
Original publication
A randomized, double‐blind, crossover study of the effect of the fluoroquinolone moxifloxacin on glucose levels and insulin sensitivity in young men and women. Diabetes Obes Metab. Published 12 September 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →